4.6 Review

Recent advances of the mammalian target of rapamycin signaling in mesenchymal stem cells

Journal

FRONTIERS IN GENETICS
Volume 13, Issue -, Pages -

Publisher

FRONTIERS MEDIA SA
DOI: 10.3389/fgene.2022.970699

Keywords

mTOR; mesenchymal stem cells; differentiation; immune response; ageing-related diseases; therapeutic target

Funding

  1. Graduate Scientific Research Innovation Project of Chongqing
  2. Natural Science Foundation of Chongqing [CYS22255]
  3. [cstc2022ycjh-bgzxm0113]

Ask authors/readers for more resources

This review discusses the role of mTOR in mesenchymal stem cells and its potential for treating ageing-related diseases.
Mammalian target of rapamycin (mTOR) is a serine/threonine kinase involved in a variety of cellular functions, such as cell proliferation, metabolism, autophagy, survival and cytoskeletal organization. Furthermore, mTOR is made up of three multisubunit complexes, mTOR complex 1, mTOR complex 2, and putative mTOR complex 3. In recent years, increasing evidence has suggested that mTOR plays important roles in the differentiation and immune responses of mesenchymal stem cells (MSCs). In addition, mTOR is a vital regulator of pivotal cellular and physiological functions, such as cell metabolism, survival and ageing, where it has emerged as a novel therapeutic target for ageing-related diseases. Therefore, the mTOR signaling may develop a large impact on the treatment of ageing-related diseases with MSCs. In this review, we discuss prospects for future research in this field.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.6
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available